Hypertensive Kidney Disease Mechanisms and Management

Hypertensive kidney disease arises from the sustained elevation of systemic blood pressure and involves a convergence of haemodynamic, inflammatory and metabolic pathways that culminate in progressive renal injury. Persistent hypertension induces structural alterations in preglomerular arterioles and glomerular capillaries, provoking endothelial dysfunction and peritubular hypoxia. Overactivation of the renin–angiotensin–aldosterone system amplifies oxidative stress and pro-inflammatory signalling, driving podocyte injury, mesangial expansion and epithelial–mesenchymal transition of tubular epithelial cells. These processes foster tubulointerstitial fibrosis and glomerulosclerosis, leading to decline in glomerular filtration and progression to end-stage renal disease. Management strategies centre on rigorous blood pressure control, principally through angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and mineralocorticoid receptor antagonists. Emerging therapies include sodium–glucose cotransporter-2 inhibitors, endothelin receptor antagonists and agents targeting inflammatory mediators or fibrotic pathways. Advances in biomarker discovery, notably circulating microRNAs and inflammatory cytokine profiles, promise to enhance early detection and individualise treatment. A holistic approach combining pharmacological modulation of haemodynamic stress, metabolic derangements and immune activation underpins current and future efforts to mitigate the global burden of hypertensive nephropathy.

Research from Nature Portfolio

Recent studies have delineated a circulating microRNA-driven regulatory axis contributing to angiotensin II-induced renal inflammation and fibrosis. Elevated levels of miR-103a-3p were observed in both patients and animal models of hypertensive nephropathy, correlating with diminished expression of the kinase SNRK in glomerular endothelial cells. Loss of SNRK releases inhibition on NF-κB/p65, thereby intensifying inflammatory cytokine production and extracellular matrix deposition. This work identifies the miR-103a-3p/SNRK/NF-κB pathway as a critical mediator of blood pressure-associated renal damage and suggests that modulation of specific microRNAs may offer a novel therapeutic avenue.

Hypertensive Kidney Disease Mechanisms and Management publication trend

The graph below shows the total number of articles in hypertensive kidney disease mechanisms and management across all publications each year (not limited to Nature Index journals).

Technical terms

microRNA: Short non-coding RNA molecules that regulate gene expression post-transcriptionally.

Renin–Angiotensin–Aldosterone System (RAAS): Hormonal cascade governing blood pressure, fluid balance and vascular tone.

NF-κB: Nuclear transcription factor central to the regulation of inflammatory gene expression.

Epithelial–Mesenchymal Transition (EMT): Process by which epithelial cells acquire a mesenchymal, fibrogenic phenotype.

Tubulointerstitial Fibrosis: Excessive deposition of extracellular matrix within the renal interstitium leading to tissue scarring.

References

1. Mechanisms of inflammation modulation by different immune cells in hypertensive nephropathy. Frontiers in Immunology (2024).
2. Renal Inflammation, Oxidative Stress, and Metabolic Abnormalities During the Initial Stages of Hypertension in Spontaneously Hypertensive Rats. Cells (2024).
3. Circulating miR-103a-3p contributes to angiotensin II-induced renal inflammation and fibrosis via a SNRK/NF-κB/p65 regulatory axis. Nature Communications (2019).